Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients

NCT04222465 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04222465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04222465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 19, 2020
Completion date
November 13, 2020
Enrollment
207 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms